Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Meningioma: early-phase trial registry
13 of 22 indexed Meningioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 13 currently recruiting · #756 of 28,707 conditions by registered trial count
Meningioma: 22 US clinical trials tracked, 13 recruiting.
Meningioma is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Nader Sanai, running 2 of these trials.
Enrollment posture brief
Registry condition meningioma
OPEN 13 | RECR 59% | LATE 2 | EARLY 12 | RANK #756 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Cholangiocarcinoma (59% recruiting · 61 trials)
Meningioma lists 13 open slots (59% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Meningioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Meningioma is recruiting above its size-band peers.
13 of 22 indexed trials (59.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Meningioma trials is spread across many organizations.
Nader Sanai accounts for 2 of 22 trials (9.1%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Meningioma trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 22 trials that report a genuine target (sentinel values excluded). 15 of those (68.2%) plan for fewer than 100 participants.
-
Meningioma research is mostly interventional.
20 interventional and 2 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Long-Term Longitudinal QoL in Patients Undergoing EEA
Ohio State University
NCT04087902
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
Jona Hattangadi-Gluth
NCT05576103
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Weill Medical College of Cornell University
NCT04081701
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
NCT06132685
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
Abemaciclib in Newly Diagnosed Meningioma Patients
Nader Sanai
NCT05940493
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
NCT05278208
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
Javier Villaneuva-Meyer, MD
NCT06014905
Evaluation of the CONVIVO System
Dartmouth-Hitchcock Medical Center
NCT05139277
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
NCT05425004
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
University of California, San Francisco
NCT06557512
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
NCT06650163
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Weill Medical College of Cornell University
NCT06377371
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Scott R. Plotkin, MD, PhD
NCT04374305
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Nader Sanai
NCT02933736
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
NCT03971461
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
Massachusetts General Hospital
NCT02693990
Information Presentation Formats
Carnegie Mellon University
NCT02267928
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
NCT01347307
Monthly SOM230C for Recurrent or Progressive Meningioma
Patrick Y. Wen, MD
NCT00859040
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
NCT02831257
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
M.D. Anderson Cancer Center
NCT03953131
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Meningioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Meningioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Meningioma page
22 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Meningioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nader Sanai sponsors the most Meningioma trials on record, review their full trial history before evaluating a specific study. See Nader Sanai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Meningioma condition card totals 22 registered trials; most-linked intervention Magnetic Resonance Imaging; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.